Literature DB >> 25034337

Simulations suggest pharmacological methods for rescuing long-term potentiation.

Paul Smolen1, Douglas A Baxter2, John H Byrne2.   

Abstract

Congenital cognitive dysfunctions are frequently due to deficits in molecular pathways that underlie the induction or maintenance of synaptic plasticity. For example, Rubinstein-Taybi syndrome (RTS) is due to a mutation in cbp, encoding the histone acetyltransferase CREB-binding protein (CBP). CBP is a transcriptional co-activator for CREB, and induction of CREB-dependent transcription plays a key role in long-term memory (LTM). In animal models of RTS, mutations of cbp impair LTM and late-phase long-term potentiation (LTP). As a step toward exploring plausible intervention strategies to rescue the deficits in LTP, we extended our previous model of LTP induction to describe histone acetylation and simulated LTP impairment due to cbp mutation. Plausible drug effects were simulated by model parameter changes, and many increased LTP. However no parameter variation consistent with a effect of a known drug class fully restored LTP. Thus we examined paired parameter variations consistent with effects of known drugs. A pair that simulated the effects of a phosphodiesterase inhibitor (slowing cAMP degradation) concurrent with a deacetylase inhibitor (prolonging histone acetylation) restored normal LTP. Importantly these paired parameter changes did not alter basal synaptic weight. A pair that simulated the effects of a phosphodiesterase inhibitor and an acetyltransferase activator was similarly effective. For both pairs strong additive synergism was present. The effect of the combination was greater than the summed effect of the separate parameter changes. These results suggest that promoting histone acetylation while simultaneously slowing the degradation of cAMP may constitute a promising strategy for restoring deficits in LTP that may be associated with learning deficits in RTS. More generally these results illustrate how the strategy of combining modeling and empirical studies may provide insights into the design of effective therapies for improving long-term synaptic plasticity and learning associated with cognitive disorders.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive disorders; Combination therapy; Drug synergism; Long-term memory; Rubinstein–Taybi syndrome

Mesh:

Substances:

Year:  2014        PMID: 25034337      PMCID: PMC4162763          DOI: 10.1016/j.jtbi.2014.07.006

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  56 in total

Review 1.  Epigenetic dysregulation in cognitive disorders.

Authors:  Johannes Gräff; Isabelle M Mansuy
Journal:  Eur J Neurosci       Date:  2009-06-10       Impact factor: 3.386

2.  A model of the roles of essential kinases in the induction and expression of late long-term potentiation.

Authors:  Paul Smolen; Douglas A Baxter; John H Byrne
Journal:  Biophys J       Date:  2006-01-13       Impact factor: 4.033

3.  Synaptic tagging and long-term potentiation.

Authors:  U Frey; R G Morris
Journal:  Nature       Date:  1997-02-06       Impact factor: 49.962

Review 4.  Phosphodiesterase inhibitors for cognitive enhancement.

Authors:  Gregory M Rose; Allen Hopper; Michael De Vivo; Ashok Tehim
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

5.  Is persistent activity of calcium/calmodulin-dependent kinase required for the maintenance of LTP?

Authors:  H X Chen; N Otmakhov; S Strack; R J Colbran; J E Lisman
Journal:  J Neurophysiol       Date:  2001-04       Impact factor: 2.714

6.  Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.

Authors:  Charles E Foulds; Mary L Nelson; Adam G Blaszczak; Barbara J Graves
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 7.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Authors:  Aleksey G Kazantsev; Leslie M Thompson
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

8.  CBP histone acetyltransferase activity is a critical component of memory consolidation.

Authors:  Edward Korzus; Michael G Rosenfeld; Mark Mayford
Journal:  Neuron       Date:  2004-06-24       Impact factor: 17.173

9.  Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.

Authors:  Juan M Alarcón; Gaël Malleret; Khalid Touzani; Svetlana Vronskaya; Shunsuke Ishii; Eric R Kandel; Angel Barco
Journal:  Neuron       Date:  2004-06-24       Impact factor: 17.173

10.  Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.

Authors:  H Akiko Popiel; Toshihide Takeuchi; Hiromi Fujita; Kazuhiro Yamamoto; Chiyomi Ito; Hiroshi Yamane; Shin-ichi Muramatsu; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more
  7 in total

1.  A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.

Authors:  Mar Cuadrado-Tejedor; Carolina Garcia-Barroso; Juan A Sánchez-Arias; Obdulia Rabal; Marta Pérez-González; Sara Mederos; Ana Ugarte; Rafael Franco; Victor Segura; Gertrudis Perea; Julen Oyarzabal; Ana Garcia-Osta
Journal:  Neuropsychopharmacology       Date:  2016-08-23       Impact factor: 7.853

Review 2.  The right time to learn: mechanisms and optimization of spaced learning.

Authors:  Paul Smolen; Yili Zhang; John H Byrne
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870

3.  Discovering novel phenotypes with automatically inferred dynamic models: a partial melanocyte conversion in Xenopus.

Authors:  Daniel Lobo; Maria Lobikin; Michael Levin
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

4.  β-adrenergic signaling broadly contributes to LTP induction.

Authors:  Joanna Jȩdrzejewska-Szmek; Vincent Luczak; Ted Abel; Kim T Blackwell
Journal:  PLoS Comput Biol       Date:  2017-07-24       Impact factor: 4.475

5.  Superior long-term synaptic memory induced by combining dual pharmacological activation of PKA and ERK with an enhanced training protocol.

Authors:  Rong-Yu Liu; Curtis Neveu; Paul Smolen; Leonard J Cleary; John H Byrne
Journal:  Learn Mem       Date:  2017-06-15       Impact factor: 2.460

6.  Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.

Authors:  M Cuadrado-Tejedor; C Garcia-Barroso; J Oyarzabal; A Garcia-Osta; J Sanzhez-Arias; S Mederos; O Rabal; A Ugarte; R Franco; M Pascual-Lucas; V Segura; G Perea
Journal:  Clin Epigenetics       Date:  2015-10-08       Impact factor: 6.551

7.  Modeling suggests combined-drug treatments for disorders impairing synaptic plasticity via shared signaling pathways.

Authors:  Paul Smolen; Marcelo A Wood; Douglas A Baxter; John H Byrne
Journal:  J Comput Neurosci       Date:  2020-11-11       Impact factor: 1.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.